Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world
population. The purpose of this pilot study is to evaluate the effect and the safety of
Tildrakizumab in adult participants with vitiligo.